Clinical Trial Update: A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia [Phase 3]

View source ↗

Summary

A Phase 3, randomized, double-blind, placebo-controlled withdrawal study of MCI-196 in chronic kidney disease patients on dialysis with hyperphosphatemia has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• MCI-196

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease, Dialysis | Phase 3 | Status: COMPLETED | Results posted: 2014-07-25